Case Report: A potential novel treatment for drug-induced acute interstitial nephritis: Benralizumab

  • Alexander Saadia
  • , Ron Wald
  • , Assaf Potruch
  • , Galina Pizov
  • , Karen Meir
  • , Kobi Gorin
  • , Inon Sarig
  • , Eyal Ben Dori
  • , Limor Rubin
  • , Yaarit Ribak
  • , Odded Shamriz
  • , Yuval Tal
  • , Aviv Talmon*
  • *Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

Abstract

A 55-year-old man presented to the emergency department (ED) with diffuse abdominal pain, vomiting, and anuria following a night of heavy alcohol intake. The patient’s medical history included hypertension. Two weeks prior to presentation, he was prescribed etoricoxib for back pain. On presentation, he was found to have severe acute kidney injury, and dialysis was initiated. Renal biopsy showed acute interstitial nephritis with numerous eosinophilic infiltrates. Despite stopping etoricoxib and initiating high-dose steroids, kidney function did not improve. The administration of benralizumab—an anti-CD125 antibody—resulted in rapid and complete recovery of kidney function. This case report highlights the potential role of benralizumab in the treatment of drug-induced interstitial nephritis with eosinophiluria.

Original languageEnglish
Article number1720992
JournalFrontiers in Immunology
Volume16
DOIs
StatePublished - 2025

Bibliographical note

Publisher Copyright:
Copyright © 2025 Saadia, Wald, Potruch, Pizov, Meir, Gorin, Sarig, Dori, Rubin, Ribak, Shamriz, Tal and Talmon.

Keywords

  • IL-5 antibody
  • acute interstitial nephritis (AIN)
  • acute kidney injury
  • benralizumab
  • dialysis

Fingerprint

Dive into the research topics of 'Case Report: A potential novel treatment for drug-induced acute interstitial nephritis: Benralizumab'. Together they form a unique fingerprint.

Cite this